84 related articles for article (PubMed ID: 25139496)
1. Serum levels of soluble Fas ligand, granzyme B and cytochrome c during adjuvant chemotherapy of breast cancer.
Kadam CY; Abhang SA
Clin Chim Acta; 2015 Jan; 438():98-102. PubMed ID: 25139496
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis Markers in Breast Cancer Therapy.
Kadam CY; Abhang SA
Adv Clin Chem; 2016; 74():143-93. PubMed ID: 27117663
[TBL] [Abstract][Full Text] [Related]
3. Circulating soluble Fas concentration in breast cancer patients.
Ueno T; Toi M; Tominaga T
Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
[TBL] [Abstract][Full Text] [Related]
4. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients.
Shimizu M; Kondo M; Ito Y; Kume H; Suzuki R; Yamaki K
Cancer Detect Prev; 2005; 29(2):175-80. PubMed ID: 15829378
[TBL] [Abstract][Full Text] [Related]
5. Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C.
Pelli N; Floreani A; Torre F; Delfino A; Baragiotta A; Contini P; Basso M; Picciotto A
Clin Exp Immunol; 2007 Apr; 148(1):85-9. PubMed ID: 17302732
[TBL] [Abstract][Full Text] [Related]
6. To study the significance of apoptotic enzyme granzyme H in breast cancer patients.
Razvi NZ; Khurshid R; Nagra SA
J Ayub Med Coll Abbottabad; 2008; 20(1):84-6. PubMed ID: 19024195
[TBL] [Abstract][Full Text] [Related]
7. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic reaction mediators: granzymes A and B in women with ovarian cancer.
Mielczarek-Palacz A; Sikora J; Kondera-Anasz Z; Bednarek I
Tissue Antigens; 2014 Jun; 83(6):409-13. PubMed ID: 24673566
[TBL] [Abstract][Full Text] [Related]
9. Soluble VCAM-1 and E-selectin in breast cancer: relationship with staging and with the detection of circulating cancer cells.
Silva HC; Garcao F; Coutinho EC; De Oliveira CF; Regateiro FJ
Neoplasma; 2006; 53(6):538-43. PubMed ID: 17167725
[TBL] [Abstract][Full Text] [Related]
10. The relation between soluble apoptotic proteins and subclinical cardiotoxicity in adjuvant-treated breast cancer patients.
Perik PJ; De Vries EG; Boomsma F; Messerschmidt J; Van Veldhuisen DJ; Sleijfer DT; Gietema JA; Van der Graaf WT
Anticancer Res; 2006; 26(5B):3803-11. PubMed ID: 17094405
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
Naumnik W; Izycki T; Ossolinska M; Chyczewska E
Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome.
Hashimoto S; Kobayashi A; Kooguchi K; Kitamura Y; Onodera H; Nakajima H
Am J Respir Crit Care Med; 2000 Jan; 161(1):237-43. PubMed ID: 10619826
[TBL] [Abstract][Full Text] [Related]
13. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis markers soluble Fas (sFas), Fas Ligand (FasL) and sFas/FasL ratio in patients with bacteremia: a prospective cohort study.
Huttunen R; Syrjänen J; Vuento R; Laine J; Hurme M; Aittoniemi J
J Infect; 2012 Mar; 64(3):276-81. PubMed ID: 22207003
[TBL] [Abstract][Full Text] [Related]
15. Perforin, granzyme B, and FasL expression by peripheral blood T lymphocytes in emphysema.
Morissette MC; Parent J; Milot J
Respir Res; 2007 Sep; 8(1):62. PubMed ID: 17822550
[TBL] [Abstract][Full Text] [Related]
16. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer.
Zhang B; Sun T; Xue L; Han X; Zhang B; Lu N; Shi Y; Tan W; Zhou Y; Zhao D; Zhang X; Guo Y; Lin D
Carcinogenesis; 2007 May; 28(5):1067-73. PubMed ID: 17183065
[TBL] [Abstract][Full Text] [Related]
17. Comparison of caspase-8, granzyme B and cytochrome C apoptosis biomarker levels in orthopedic trauma patients.
Pazarcı Ö; Aydin H; Kılınç S
Ulus Travma Acil Cerrahi Derg; 2020 Mar; 26(2):274-279. PubMed ID: 32185754
[TBL] [Abstract][Full Text] [Related]
18. Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer.
Lu P; Zhu XQ; Xu ZL; Zhou Q; Zhang J; Wu F
Surgery; 2009 Mar; 145(3):286-93. PubMed ID: 19231581
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
20. Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?--a prospective clinical study.
Chintamani ; Singhal V; Singh JP; Lyall A; Saxena S; Bansal A
BMC Cancer; 2004 Aug; 4():48. PubMed ID: 15310398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
